Targets and Emerging Therapies for Schizophrenia

Covering a wide range of receptors and molecular targets, this book provides a comprehensive resource for neuro-drug discovery and molecular targets for schizophrenia. Focusing on current research and applications, the text describes novel mechanisms of action that can overcome shortcomings in existing schizophrenia drugs. It discusses topics like prevalence and etiology, renewed interest in untreated symptoms. It also lays out each major mechanistic hypothesis, describing both neurobiological and chemical aspects of associated pharmacological targets. This text offers a peerless integration of chemistry, biology, and pharmacology for effective drug targeting and discovery.

Jeffrey S. Albert, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies. Michael W. Wood, PhD, is an External Collaborations Director in AstraZenecas neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.